12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Affibody, Swedish Orphan Biovitrum deal

The companies partnered to discover and develop up to five treatments for autoimmune and inflammatory diseases where IL-1 is implicated. Swedish Orphan has a two-year option to license programs developed under the deal. Affibody will be responsible through...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >